Skip to main content
D.Western Therapeutics Institute, Inc. logo

D.Western Therapeutics Institute, Inc. — Investor Relations & Filings

Ticker · 4576 ISIN · JP3548740004 LEI · 529900V121NGDHXFA434 T Professional, scientific and technical activities
Open in API
Filings indexed 71 across all filing types
Latest filing 2026-05-01 Regulatory Filings
Country JP Japan
Listing T 4576

About D.Western Therapeutics Institute, Inc.

https://dwti.co.jp/english/

D.Western Therapeutics Institute, Inc. is a biotechnology company focused on the research, discovery, and development of innovative pharmaceutical drugs. The company's core technology is centered on a proprietary compound library with a primary focus on inhibitors, particularly protein kinase inhibitors. Its drug discovery and development business aims to provide patients with more effective and beneficial treatments than conventional drugs. A notable product developed from its research is the ophthalmic solution GLANATEC.

Recent filings

Filing Released Lang Actions
第13回新株予約権（行使価額修正条項付）の月間行使状況に関するお知らせ
Regulatory Filings
2026-05-01 Japanese
譲渡制限付株式報酬としての新株式発行に関するお知らせ
Regulatory Filings
2026-04-17 Japanese
訂正有価証券届出書（組込方式）
Share Issue/Capital Change Classification · 90% confidence The document is a Japanese corrected securities registration statement (有価証券届出書) for a third‐party allotment of 2,150,500 new shares, detailing issuance price, capital increase, allotment conditions, and usage of proceeds. This is not a high‐level annual or interim report, nor an earnings release or management change notice. It is a full prospectus for a share issuance, matching the definition of “Share Issue/Capital Change” (SHA).
2026-03-27 Japanese
有価証券届出書（組込方式）
Share Issue/Capital Change Classification · 95% confidence The document is a Japanese Securities Registration Statement (“有価証券届出書”) filed on March 25, 2026, detailing a third‐party allotment of new shares (number of shares, issue price, capital increase, underwriter details, use of proceeds, dilution impact, and related agreements). It is a full filing concerning the issuance of new equity (capital change), not simply an announcement or investor presentation. This aligns precisely with the Share Issue/Capital Change category (SHA).
2026-03-25 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is titled '確認書' (Confirmation Letter) and is submitted under the Financial Instruments and Exchange Act. It serves as an officer certification by the President of D.Western Therapeutics Institute, Inc., confirming the accuracy of the Annual Securities Report (有価証券報告書) for the 28th fiscal period. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a specific report, should be classified as Regulatory Filings (RNS). FY 28
2026-03-23 Japanese
有価証券報告書－第28期(2025/01/01－2025/12/31)
Annual Report Classification · 100% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which is the standard Japanese equivalent of an Annual Report (10-K). It includes a cover page with the filing date (2026-03-23), the fiscal period (2025-01-01 to 2025-12-31), and detailed financial tables (consolidated and non-consolidated). It is not an announcement or a summary, but the full report itself. FY 2025
2026-03-23 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.